Daewoong's subsidiary Daewoong Pharmaceutical receives IND approval for Phase 3 trial of Fexuclue for gastric ulcer
Daewoong's subsidiary Daewoong Pharmaceutical has received approval from the Korea Ministry of Food and Drug Safety for a multinational Phase 3 clinical trial plan to add a gastric ulcer treatment indication for its existing new drug Fexuclue 40mg.
The trial involves 384 patients over approximately 21 months, aiming to demonstrate non-inferiority compared to an active control. Success would expand the drug's label, potentially boosting sales.
However, the statistical probability of final approval for a clinical trial drug is only about 10%, and unexpected results could lead to changes or abandonment of commercialization plans. This uncertainty may contribute to stock price volatility.
[AI Summary]Daewoong's subsidiary received Phase 3 approval for a label expansion of an existing drug, but with low success rates and no capital structure changes, the short-term impact on shareholder value is limited. Long-term upside exists if the trial succeeds, but high uncertainty remains.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Approval of Phase 3 Clinical Trial Plan (IND) for Addition of Indication of Fexuclue (Fexuclue Tablet) for Treatment of Gastric Ulcer)